Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride

References

• Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):39–49. doi: 10.1016/s0169-409x(97)00060-4.
   PubMed Web of Science ®Google Scholar
• Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012;134(3):366–379. doi: 10.1016/j.pharmthera.2012.03.003.
   PubMed Web of Science ®Google Scholar
• Schmidt MC, Rothen-Rutishauser B, Rist B, et al. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry. 1998;37(47):16582–16590. doi: 10.1021/bi981219h.
   PubMed Web of Science ®Google Scholar
• Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst. 1996;13(1–2):85–184.
   PubMed Web of Science ®Google Scholar
• Lopes T, Dias JS, Marcelino J, et al. An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic. BJU Int. 2001;87(4):322–325. doi: 10.1046/j.1464-410x.2001.00068.x.
   PubMed Web of Science ®Google Scholar
• Hinchcliffe M, Illum L. Intranasal insulin delivery and therapy. Adv Drug Deliv Rev. 1999;35(2–3):199–234. doi: 10.1016/s0169-409x(98)00073-8.
   PubMed Web of Science ®Google Scholar
• CAIV-T. Influenza vaccine live intranasal. Influenza virus vaccine live intranasal -MedImmune vaccines. Drugs R&D. 2013;4(5):312–319.
   Google Scholar
• Khan AR, Liu M, Khan W, et al. Progress in brain targeting drug delivery system by nasal route. J Control Release. 2017;268:364–389. doi: 10.1016/j.jconrel.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1–2):1–24. doi: 10.1016/j.ijpharm.2007.03.025.
   PubMed Web of Science ®Google Scholar
• Rojanasakul Y, Wang LY, Bhat M, et al. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res. 1992;9(8):1029–1034. doi: 10.1023/a:1015802427428.
   PubMed Web of Science ®Google Scholar
• Bitter C, Suter- Zimmermann K, Surber C. Nasal drug delivery in humans. In: Surber C, Elsner P, Farage MA, editors. Topical applications and the mucosa; Current problems in dermatology. Basel: Karger; 2011. p. 20–35.
   Google Scholar
• Wermeling DP, Miller J. Intranasal drug delivery. In: Rathbone MJ, editor. Modified-release drug delivery system. New York: Marcel Dekker; 2002. p. 731–732.
   Google Scholar
• Yurtdaş-Kırımlıoğlu G. A promising approach to design thermosensitive in situ gel based on solid dispersions of desloratadine with kolliphor® 188 and pluronic® F127. J Therm Anal Calorim. 2022;147(2):1307–1327. doi: 10.1007/s10973-020-10460-0.
   Web of Science ®Google Scholar
• Kaur P, Garg T, Rath G, et al. In situ nasal gel drug delivery: a novel approach for brain targeting. Artif Cells Nanomed Biotechnol. 2015;44(4):1167–1176. doi: 10.3109/21691401.2015.1012260.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zuo Z, Cheung CKC, et al. Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery. Int J Pharm. 2019;559:86–101. doi: 10.1016/j.ijpharm.2019.01.030.
   PubMedGoogle Scholar
• Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm. 2008;355(1–2):1–18. doi: 10.1016/j.ijpharm.2008.01.057.
   PubMedGoogle Scholar
• Khan S, Ullah A, Ullah K, et al. Insight into hydrogels. Des Monomers Polym. 2016;19(5):456–478. doi: 10.1080/15685551.2016.1169380.
   Google Scholar
• Jeong B, Kim SW, Bae YH. Thermosensitive sol–gel reversible hydrogels. Adv Drug Deliv Rev. 2012;64:154–162. doi: 10.1016/j.addr.2012.09.012.
   Web of Science ®Google Scholar
• Singh RMP, Kumar A, Pathak K. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery. Expert Opin Drug Deliv. 2012;10(1):115–130. doi: 10.1517/17425247.2013.746659.
   PubMed Web of Science ®Google Scholar
• Mortensen SK, Pedersen J. Structural study on the micelle formation of poly (ethy1ene oxide)-poly (propylene oxide)-poly (ethy1ene oxide) triblock copolymer in aqueous solution. Macromolecules. 1993;26(4):805–812. doi: 10.1021/ma00056a035.
   Web of Science ®Google Scholar
• Cabana A, Kadi AA, Juhasz J. Study of the gelation process of polyethylene oxide a – polypropylene oxide b – polyethylene oxide a copolymer (poloxamer 407) aqueous solutions. J Colloid Interface Sci. 1997;190(2):307–312. doi: 10.1006/jcis.1997.4880.
   PubMed Web of Science ®Google Scholar
• Qui Y, Hamilton SK, Temenoff J. Improving mechanical properties of injectable polymers and composites. Inject Biomater. 2011:61–91. doi:10.1533/9780857091376.1.61.
   Google Scholar
• Sosnik A, Cohn D, Román J, et al. Crosslinkable PEO-PPO-PEO-based reverse thermo-responsive gels as potentially injectable materials. J Biomater Sci Polym Ed. 2003;14(3):227–239. doi: 10.1163/156856203763572680.
   PubMed Web of Science ®Google Scholar
• Ozsoy Y, Güngör S. Nasal route: an alternative approach for antiemetic drug delivery. Expert Opin Drug Deliv. 2011;8(11):1439–1453. doi: 10.1517/17425247.2011.607437.
   PubMed Web of Science ®Google Scholar
• Brayfield A, editor. Martindale the complete drug reference. 38th ed. London: Pharmaceutical Press; 2014. p. 638–625.
   Google Scholar
• McDonough JA, Persyn JT, Nino JA, et al. Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication. J Microencapsul. 2007;24(2):109–116. doi: 10.1080/09687860600945628.
   PubMed Web of Science ®Google Scholar
• Hafner A, Filipović-Grcić J, Voinovich D, et al. Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm. 2007;33(4):427–436. doi: 10.1080/03639040600920309.
   PubMed Web of Science ®Google Scholar
• Iliger SR, Demappa T. Formulation and characterization of mucoadhesive microspheres of promethazine hydrochloride for nasal delivery. J Pharm Res. 2011;4(1):276–279.
   Google Scholar
• Rowe RC, Sheskey PJ, Owen, SC, editors. Handbook of pharmaceutical excipients. 5th ed. London: Pharmaceutical Press; 2006. p. 506.
   Google Scholar
• Karavasili C, Fatouros DG. Smart materials: in situ gel-forming systems for nasal delivery. Drug Discov Today. 2016;21(1):157–166. doi: 10.1016/j.drudis.2015.10.016.
   PubMed Web of Science ®Google Scholar
• Galgatte UC, Chaudhari PD. Preformulation study of poloxamer 407 gels: effect of additives. Int J Pharm Pharm Sci. 2013;6(1):130–133.
   Google Scholar
• Chonkar A, Nayak U, Udupa N. Smart polymers in nasal drug delivery. Indian J Pharm Sci. 2015;77(4):367–375. doi: 10.4103/0250-474x.164770.
   PubMed Web of Science ®Google Scholar
• Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):89–116. doi: 10.1016/s0169-409x(97)00063-x.
   PubMed Web of Science ®Google Scholar
• Steele G. Preformulation as an aid to product design in early drug development. In: Gibson M, editor. Pharmaceutical preformulation and formulation. A practical guide from candidate drug selection to commercial dosage form. New York: Informa Healthcare; 2009. p. 188–246.
   Google Scholar
• International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Q3B(R2) Impurities in new drug product. Amsterdam: The European Medicine Agency; 2006.
   Google Scholar
• Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6(6):571–582. doi: 10.1002/JBM.820060609.
   PubMed Web of Science ®Google Scholar
• Bhandwalkar MJ, Avachat AM. Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation. AAPS PharmSciTech. 2013;14(1):101–110. doi: 10.1208/s12249-012-9893-1.
   PubMed Web of Science ®Google Scholar
• Mali KK, Dhawale SC, Dias RJ, et al. Nasal mucoadhesive in-situ gel of granisetron hydrochloride using natural polymers. J App Pharm Sci. 2015;5(7):084–093. doi: 10.7324/JAPS.2015.50714.
   Google Scholar
• Qian S, Cheong Wong Y, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int J Pharm. 2014;468(1–2):272–282. doi: 10.1016/j.ijpharm.2014.04.015.
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use Q8 (R2) pharmaceutical development. Amsterdam: European medicines agency; 2006.
   Google Scholar
• Lawrence XY, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783. doi: 10.1208/s12248-014-9598-3.
   PubMed Web of Science ®Google Scholar
• Mishra V, Thakur S, Patil A, et al. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018;15(8):737–758. doi: 10.1080/17425247.2018.1504768.
   PubMed Web of Science ®Google Scholar
• Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci. 2016;12(1):1–8. doi: 10.1016/j.ajps.2016.07.006.
   PubMed Web of Science ®Google Scholar
• Beg S, Rehman Z. Central composite designs and their applications in pharmaceutical product development. In: Beg S, editor. Design of experiments for pharmaceutical product development. Singapore: Springer; 2021. p. 63–76.
   Google Scholar
• Mura P, Mennini N, Nativi C, et al. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin. Eur J Pharm Biopharm. 2017;122:54–61. doi: 10.1016/j.ejpb.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Dias R, Mali KK, Havaldar V. Formulation and evaluation of thermoreversible mucoadhesive nasal gels of metoclopramide hydrochloride. Lat Am J Pharm. 2010;29(3):354–361.
   Web of Science ®Google Scholar
• Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv. 2013;21(1):62–73. doi: 10.3109/10717544.2013.849778.
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Q1 (R2). Amsterdam: The European Medicines Agency; 2003.
   Google Scholar
• Shelke S, Shahi S, Jalalpure S, et al. Formulation and evaluation of thermoreversible mucoadhesive in situ gel for intranasal delivery of naratriptan hydrochloride. J Drug Deliv Sci Technol. 2015;29:1–32.
   Web of Science ®Google Scholar
• Altuntaş G, Yener E. Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis. AAPS PharmSciTech. 2017;18(7):2673–2682. doi: 10.1208/s12249-017-0747-8.
   PubMed Web of Science ®Google Scholar
• Verekar RR, Gurav SS, Bolmal U. Thermosensitive mucoadhesive in situ gel for intranasal delivery of almotriptan malate: formulation, characterization and evaluation. J Drug Deliv Sci Technol. 2020;58:101778. doi: 10.1016/j.jddst.2020.101778.
   Web of Science ®Google Scholar
• Zahir-Jouzdani F, Wolf JD, Atyabi F, et al. In situ gelling and mucoadhesive polymers: why do they need each other? Expert Opin Drug Deliv. 2018;15(10):1007–1019. doi: 10.1080/17425247.2018.1517741.
   PubMed Web of Science ®Google Scholar
• Rehman S, Nabi B, Zafar A, et al. Intranasal delivery of mucoadhesive nanocarriers; a viable option for Parkinson’s disease treatment? Expert Opin Drug Deliv. 2019;16(12):1355–1366. doi: 10.1080/17425247.2019.1684895.
   PubMed Web of Science ®Google Scholar
• Abdeltawab H, Svirskis D, Sharma M. Formulation strategies to modulate drug release from poloxamer based in-situ gelling systems. Expert Opin Drug Deliv. 2020;17(4):495–509. doi: 10.1080/17425247.2020.1731469.
   PubMed Web of Science ®Google Scholar
• Sousa J, Alves G, Oliveira P, et al. Intranasal delivery of ciprofloxacin to rats: a topical approach using a thermoreversible in situ gel. Eur J Pharm Sci. 2017;97:30–37. doi: 10.1016/j.ejps.2016.10.033.
   PubMed Web of Science ®Google Scholar
• Rao M, Agrawal K, Shirsath G. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson’s disease. Drug Dev Ind Pharm. 2016;43(1):142–150. doi: 10.1080/03639045.2016.1225754.
   PubMed Web of Science ®Google Scholar
• Khattab A, Marzok S, Ibrahim M. Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of latanoprost: antiglaucoma efficacy and stability approaches. J Drug Deliv Sci Techno. 2019;53:101134. doi: 10.1016/j.jddst.2019.101134.
   Web of Science ®Google Scholar
• Patel N, Thakkar V, Metalia V, et al. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Drug Dev Ind Pharm. 2016;42(9):1406–1423. doi: 10.3109/03639045.2015.1137306.
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Schipper NG, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):13–38. doi: 10.1016/s0169-409x(97)00059-8.
   PubMed Web of Science ®Google Scholar
• Corazza E, Pio di Cagno M, Bauer-Brandl A, et al. Drug delivery to the brain: in situ gelling formulation enhances carbamazepine diffusion through nasal mucosa models with mucin. Eur J Pharm Sci. 2022;179:106294. doi: 10.1016/j.ejps.2022.106294.
   PubMed Web of Science ®Google Scholar
• Salatin S, Alami-Milani M, Daneshgar R, et al. The intranasal gels of Box-Behnken experimental design for preparation and optimization of selegiline hydrochloride. Drug Dev Ind Pharm. 44(10):1613–1621. doi: 10.1080/03639045.2018.1483387.
   PubMed Web of Science ®Google Scholar
• Zabirowicz ES, Gan T. Pharmacology of postoperative nausea and vomiting, pharmacology and physiology for anesthesia. Elsevier; 2019. p. 684.
   Google Scholar
• Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021;607:120994. doi: 10.1016/j.ijpharm.2021.120994.
   PubMed Web of Science ®Google Scholar
• Mohsen AM, Salama AAA, Asfou MH. Cubosome-based thermosensitive in situ gelling system for intranasal administration of lamotrigine with enhanced antiepileptic efficacy. Pharm Dev Technol. 2023;28(6):520–534. doi: 10.1080/10837450.2023.2216755.
   PubMed Web of Science ®Google Scholar
• Ghori MU, Mmh S. Nasal drug delivery systems: an overview. American J Pharmacol Sci. 2015;3(5):110–119.
   Google Scholar
• Erlandsson B. Stability-indicating changes in poloxamers: the degradation of ethylene oxide-propylene oxide block copolymers at 25 and 40 C. Polym Degrad Stab. 2002;78(3):571–575. doi: 10.1016/S0141-3910(02)00233-1.
   Web of Science ®Google Scholar
• Akash MSH, Rehman K, Sun H, et al. Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist. Pharm Dev Technol. 2014;19(3):278–284. doi: 10.3109/10837450.2013.775158.
   PubMed Web of Science ®Google Scholar